Skip to main content
TipRanks
Go Ultimate75% OFF
Pepticom logo

Pepticom: Valuation, Funding & Investors

Pepticom is a leader in AI-driven peptide-based therapeutics, focusing on the development of innovative treatments for autoimmune diseases. The company is advancing its oral IL-17 inhibitor program, which includes the design of synthetic, small cyclic peptidomimetic inhibitors targeting IL-17A and IL-17F isoforms. These compounds, composed of non-natural amino acids, offer enhanced stability and extended half-life, marking significant progress in next-generation drug discovery.

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$7M
Total Funding Rounds
1
Latest Funding Amount
$7M
Latest Funding Round
Series A

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Jan 07, 2025Series A$6.60M―

Investors

Investor NameFunding Round
Japan Israel High Tech Ventures 2 LPSeries A

Similar Companies

A snapshot of private companies similar to Pepticom, helping you discover and navigate related company profiles.

Related News and Analysis